edicinal preparations containing antigens or antibodies (A61K39)

A61K39/012 - Viral antigens(12)
A61K39/018 - (4)
A61K39/02 - Bacterial antigens(283)
A61K39/07 - Bacillus(33)
A61K39/085 - (68)
A61K39/09 - Streptococcus(129)
A61K39/095 - (72)
A61K39/102 - (50)
A61K39/104 - (27)
A61K39/106 - (36)
A61K39/108 - (76)
A61K39/112 - (72)
A61K39/114 - (4)
A61K39/116 - (91)
A61K39/118 - (32)
A61K39/12 - Viral antigens(328)
A61K39/125 - (16)
A61K39/13 - Poliovirus(80)
A61K39/135 - (72)
A61K39/145 - (167)
A61K39/155 - (34)
A61K39/165 - (20)
A61K39/17 - Newcastle disease virus(58)
A61K39/175 - (15)
A61K39/187 - (22)
A61K39/193 - (6)
A61K39/20 - Rubella virus(53)
A61K39/205 - (42)
A61K39/215 - (22)
A61K39/225 - (15)
A61K39/235 - (29)
A61K39/245 - (32)
A61K39/25 - Varicella-zoster virus(20)
A61K39/255 - (19)
A61K39/265 - (24)
A61K39/275 - (31)
A61K39/285 - (19)
A61K39/29 - Hepatitis virus(180)
A61K39/295 - (93)
A61K39/35 - Allergens(61)
A61K39/36 - From pollen(16)
A61K39/38 - Antigens from snakes(94)
A61K39/385 - (84)
A61K39/395 - (1260)
A61K39/40 - Bacterial(104)
A61K39/42 - Viral(88)
ethod for production of vaccine against brucellosis of small cattle // 2642316
FIELD: biotechnology.SUBSTANCE: method for production of vaccine against the brucellosis of small cattle provides seeding and growing strain of Brucella melitensis Rev-1 on a nutritional medium, containing pancreatic digest of casein of a high decomposition degree, yeast extract, sodium chloride, glucose, glycerol, and agar-agar in the specified component ratio within 72 hours at 37°C. The grown vaccine culture is washed from the surface of the agar by a drying medium and brought to a concentration of 80-140 billion m.c. per 1 ml. It is checked for purity and dissociation, packed in ampoules and subjected to freeze-drying.EFFECT: increase in the yield of Brucella melitensis Rev-1 strain in the S-form.1 tbl, 1 ex

Fusion serpine polypeptides and methods for their application // 2642310
FIELD: biotechnology.SUBSTANCE: invention relates to the field of fusion proteins for serine proteases inhibition, and can be used in medicine. Fusion proteins having at least one human alpha-1 antitrypsin (AAT) polypeptide operably linked to an immunoglobulin Fc polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:6 are obtained.EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.18 cl, 4 dwg, 4 ex

Cancer treatment using targeted antibodies in vivo // 2642305
FIELD: biotechnology.SUBSTANCE: antibody binding to claudine 6 (CLDN6) and inhibiting tumor growth in vivo is claimed. The antibody can be used as part of a pharmaceutical composition, in a method for treatment of tumor related to cells expressing CLDN6. The invention also relates to hybridomas producing antibodies to CLDN6 deposited under the accession numbers DSM ACC3059 (GT512muMAB 36A), DSM ACC3058 (GT512muMAB 27A), DSM ACC3057 (GT512muMAB 5F2D2).EFFECT: invention effectively inhibits the growth of CLDN6-positive germ cell tumors, improves survival and prolongs life of patients with tumors.17 cl, 18 dwg, 5 ex

Immunotherapeutic compositions on the basis of yeast-muc1 and methods of their use // 2642300
FIELD: biotechnology.SUBSTANCE: fusion protein is produced which contains the MUC1 antigen having an amino acid sequence that is at least 85% identical to the sequence of SEQ ID NO: 25 or at least 95% identical to the positions 92-566 of the sequence of SEQ ID NO: 25, and where MUC1 antigen contains 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of the following amino acids L184, Y232, L233, V240, V241, L242, Y483, V497, L335, F536 and Y551.EFFECT: invention allows to effectively treat Mucin-1-expressing carcinomas, and also to prevent their metastatic progression.14 cl, 3 dwg, 5 tbl, 10 ex

Hpv chimeric particle // 2642287
FIELD: biotechnology.SUBSTANCE: chimeric virus-like particle (VLP) of human papilloma virus (HPV), and method for its production and extraction, methods for prevention or treatment of HPV infection or cervical cancer, and for induction of an immune response in the patient, including the administration of proposed HPV VLP, as well as the application of the proposed HPV VLP in these methods and in production of pharmaceuticals to implement these methods, are proposed. The proposed chimeric HPV VLPS has a diameter of about 30 nm and contains a chimeric polypeptide HPV 16 L1/L2, which consists of a polypeptide HPV 16 L1, in which the peptide HPV 16 L2 from the amino acid residue 414 is inserted. The peptide contains from 13 to 26 amino acids. The amino acids of the inserted HPV 16 L2 peptide replace the corresponding amino acids of the HPV 16 L1 polypeptide. A method is also provided for the production of said HPV VLP in a plant in which successful assembly of small chimeric HPV VLPs, having a diameter of 30 nm, takes place.EFFECT: proposed group of inventions can be used in medicine for the prevention or treatment of HPV infection or in antitumor therapy for cervical cancer.28 cl, 32 dwg, 11 tbl, 3 ex

Thrombin-binding molecules of antibodies and their application // 2642276
FIELD: pharmacology.SUBSTANCE: isolated antibody molecule, specifically binding to the thrombin exosite area 1, and an antigen-binding fragment of said antibody, are provided. The use of the antibody molecule in the manufacture of medicaments is considered. A pharmaceutical composition is described as well as a method for treating a thrombin-mediated condition.EFFECT: use in the treatment of diseases associated with thrombin.25 cl, 22 dwg, 4 tbl

Humanized antibodies, which recognize alpha-sinuclein // 2642262
FIELD: biotechnology.SUBSTANCE: antibody is described comprising a mature variable region of the heavy chain comprising three CDR according to Kabat from the sequence of SEQ ID NO: 44 and at least 90% identical to the sequence of SEQ ID NO: 44 and a light chain comprising three CDR according to Kabat from the sequence of SEQ ID NO: 45, and at least 90% identical to the sequence of SEQ ID NO: 45, where the antibody specifically binds to a human alpha-synuclein. A pharmaceutical composition comprising the described antibody is also described. A method of treating a patient having a disease with Levy bodies or having a risk of developing the disease or a method for detecting Levy bodies in a patient having a disease with Levy bodies or having a risk of developing the disease, comprising appointing to the patient an effective regimen for administering the described antibody, is provided.EFFECT: invention provides antibodies which bind to a human alpha-synuclein and can be used to treat and diagnose a disease with Levy bodies.80 cl, 6 dwg, 5 tbl, 2 ex

Recombinant chimerical ntbi polypeptide-immunogen with ability to induce neutralizing antibodies to type 1 human immunodeficiency virus and intended for use as component of vaccine against hiv-1 // 2642258
FIELD: medicine.SUBSTANCE: recombinant chimerical polypeptide-immunogen is proposed, including conservative T- and B-cell epitopes of HIV-1 and consecutive peptide fragments of p24, gp41, gp120 proteins, recognizable by wide-neutralizing 10e8, 2F5, VRC01 antibodies.EFFECT: improved HIV-specific immune response due to the inclusion of unique linear conformational epitopes imitators, recognizable by wide-neutralizing antibodies into the polypeptide-immunogen nTBI.6 dwg, 5 ex
ethod for inactivation of cattle campilobacteriosis pathogen // 2642249
FIELD: biotechnology.SUBSTANCE: method involves accumulation of Campylobacter fetus subspecies fetus cattle campilobacteriosis pathogen colonies by culturing on a nutrient medium, flushing of the Campylobacter fetus subspecies fetus campilobacteriosis pathogen colonies with 0.9% NaCl solution, inactivation of the accumulated biomass of the Campylobacter fetus subspecies fetus campilobacteriosis pathogen by an inactivator and differs by teotropine application as an inactivator, with the following ratio of components, wt %: suspension of campylobacter cells of fetus subspecies fetus serogroup in a culture medium at a concentration of 2×1010 CFU*/cm3 (culture of the Campylobacter fenus subspecies fetus cattle campilobacteriosis pathogen) - 0.5%; 0.9% NaCl solution - 99.2%; teotropin - 0.3%.EFFECT: increased activity of the compound.1 tbl
Liquid stable viral vaccines // 2641970
FIELD: veterinary medicine.SUBSTANCE: liquid stable vaccine comprises a live attenuated canine virus, 10-30% (w/v) of saccharic adjuvant, and an amino acid, wherein the liquid stable vaccine has pH value from 6.0 to 8.0. The amino acid is selected from the group consisting of arginine and methionine; if the amino acid is arginine, then its final concentration in the liquid stable vaccine is from 0.15 to 0.6 M. If the amino acid is methionine, its final concentration in the liquid stable vaccine is from 0.025 to 0.3 M. A live attenuated canine virus is selected from the group consisting of the canine distemper virus, canine adenovirus of the 2 type, canine parvovirus and canine parainfluenza virus, or any combination thereof.EFFECT: usage of the above-mentioned stabilization principle allows to produce liquid stable composition for a live attenuated canine distemper virus, canine adenovirus of the 2 type, canine parvovirus and canine parainfluenza virus.12 cl, 2 ex, 5 tbl

ultiple vaccination including serogroup c meningococci // 2641969
FIELD: medicine.SUBSTANCE: kit contains a component that is a meningococcal saccharide conjugate, a pneumococcal saccharide conjugate component, and an additional immunogenic component for administration to different sites at substantially the same time. Where: (a) the meningococcal saccharide conjugate component contains at least a capsular saccharide Neisseria meningitidis of serogroup C conjugated to the first carrier protein, but does not contain an aluminium phosphate adjuvant; (b) the pneumococcal saccharide conjugate component comprises at least one capsular saccharide of Streptococcus pneumoniae conjugated to the second carrier protein; and (c) the additional immunogenic component comprises the cell-free antigen(s) B. pertussis and an inactivated poliovirus antigen (IPV), and one or more antigens selected from diphtheria toxoid, tetanus toxoid, HBsAg and conjugated Hib saccharide, the carrier protein of at least one meningococcal saccharide conjugate and the carrier protein of at least one pneumococcal saccharide conjugate are the same.EFFECT: use of this kit allows safe introduction of conjugates of the meningococcal saccharide and conjugates of the pneumococcal saccharide simultaneously, but separately, with an additional component containing acellular antigens and inactivated poliovirus antigen.15 cl

Pharmaceutical composition for cancer treatment and prevention // 2641260
FIELD: pharmacology.SUBSTANCE: invention relates to an antibody or a binding fragment thereof that specifically binds to the CAPRIN-1 protein and has immunological reactivity to the partial CAPRIN-1 polypeptide. Also a conjugate, as well as a pharmaceutical composition and a pharmaceutical combination for treatment or prevention of a malignant tumour expressing CAPRIN-1 are disclosed. The invention also relates to a method for treatment or prevention of a cancer expressing CAPRIN-1 using the above antibody or a fragment thereof, a conjugate, a composition or a combination.EFFECT: invention enables efficient treatment or prevention of cancer expressing CAPRIN-1.19 cl, 12 ex

Heterodimerizated polypeptide // 2641256
FIELD: biotechnology.SUBSTANCE: polypeptide with cytotoxic activity, comprising an Fc region of IgG, which consists of a heterodimer containing the first polypeptide and the second polypeptide, in the amino acid sequences of which a series of mutations takes place. A pharmaceutical composition for treatment of a human disease associated with antigens with which the said polypeptide specifically interacts, comprising the said polypeptide and a medically acceptable carrier, is provided.EFFECT: group of inventions allows to optimize the effector function of the polypeptide by changing the function of the Fc region compared to the function of the Fc region of the polypeptide, which consists of a homodimer containing only the first or only the second polypeptide.7 cl, 54 dwg, 80 tbl, 29 ex
Lyophilised preparation of botulinum toxin // 2640922
FIELD: pharmacology.SUBSTANCE: pharmaceutical lyophilized preparation, including: botulinum toxin, polysorbate, and methionine, and one or more components selected from the group consisting of sugar, sugar alcohol and ionic compound taken at a specific ratio. The ionic compound selected from sodium chloride, sodium phosphate, ammonium phosphate, magnesium sulfate, sodium acetate, sodium succinate, sodium propionate and potassium phosphate, where the drug does not contain albumin and where the botulinum toxin stability is supported for at least 30 days at 40°C and 70% relative humidity (versions).EFFECT: compositions allow to maintain stability and activity of the preparation under high temperature conditions.11 cl, 6 tbl, 2 ex

A n2269/vniizzh/2015 strain of type a aphtae epizooticae foot-and-mouth disease virus for control of antigenic and immunogenic activity and for manufacture of biopreparations for diagnosis and specific prevention of type a foot-and-mouth disease // 2640261
FIELD: biotechnology.SUBSTANCE: characterized strain is isolated from the sick cattle and obtained by successive passages on sensitive hetero- and homologous cell cultures and deposited in the collection of the FGBU "VNIIZZH" under the registration number strain VIA A2269/VNIIZZH/2015 (production), (control cattle), (control swine). The presented strain is reproduced in transplantable cultures of kidney cells of the Siberian mountain ibex (PSGK-30), IB-RS-2, VNK-21. During 17-24 hours of incubation, the virus yield in these cell cultures reaches the values of 6.75-7.75 lg TCD50/cm3. The presented virus strain can be used for control of the antigenic and immunogenic activity and for manufacture of biopreparations for diagnosis and specific prevention of type A foot and mouth disease.EFFECT: with high multiplicity of infection, causes CPD after 17-24 hours, maintaining the original characteristics when passaging in cell cultures for 5 passages.5 cl, 1 dwg, 7 tbl, 7 ex

at40 antibody binding with domain i of extracellular part of epidermal her2/cd340 growth factor receptor, and its application for cancer treatment // 2640259
FIELD: biotechnology.SUBSTANCE: antibody that binds to the epidermal HER2/CD340 growth factor receptor is disclosed. Application of this antibody to treat cancer with HER2 overexpression is also considered. The antibody of the present invention binds to domain I of the extracellular portion of HER2.EFFECT: high efficiency of cancer treatment.3 cl, 4 dwg, 2 tbl, 8 ex

Vaccine // 2640258
FIELD: biotechnology.SUBSTANCE: vaccine to reduce cholesterol levels is presented, including two proprotein convertase fragments subtilisin/kexin type 9 (PCSK9), connected to a pharmaceutically acceptable carrier, in which these two fragments are: PEEDGTRFHRQA and SIPWNLERITP; EEDGTRFHRQASK and SIPWNLERITP; EEDGTRFHRQASK and SIPWNLERIT; or EEDGTRFHRQAS and SIPWNLERIT. Application of the specified vaccine for treatment and/or prevention of disorders caused by hyperlipidemia, hypercholesterolemia and/or atherosclerosis, preferably for cardiovascular disease, stroke or peripheral vessels disease is presented.EFFECT: group of inventions allows to decrease total cholesterol when using these combinations of fragments more efficiently than by using each fragment separately.8 cl, 2 dwg, 4 tbl, 3 ex

Antibodies against nerve growth factor and methods for their production and application // 2640254
FIELD: biotechnology.SUBSTANCE: invention relates to a method for production of antibodies suitable for use in cats that are specifically associated with the cat nerve growth factor (NGF) and neutralise the ability of the cat NGF to contact the cat NGF p75 or TrkA receptor and the corresponding antibodies. To implement this method, a donor antibody is obtained from a species other than a cat, the donor antibody having a binding specificity for the target antigen present in cats. Then, each amino acid residue in the sequence of the framework regions of the donor antibody is compared to each amino acid residue present at the corresponding position in the sequence of the framework regions of cat antibodies pool. Then, the identified amino acid residues in the donor antibody are replaced with the amino acid residues present at the corresponding position in the pool of cat antibodies. The resulting antibody does not contain any amino acid foreign at the corresponding position in cats, at any position within the framework regions. This invention also discloses a pharmaceutical composition and a kit containing the said antibodies for treatment of pain in cats, in particular pain associated with arthritis or osteoarthritis immune-mediated rheumatoid arthritis.EFFECT: decrease or loss of antigen-binding activity is avoided.16 cl, 17 dwg, 16 tbl, 11 ex

Bispecific anti-vegf/anti-ang-2 antibodies // 2640253
FIELD: biotechnology.SUBSTANCE: invention relates to a bispecific antibody specifically binding to a human vascular endothelial growth factor-VEGF and human angiopoietin-2-ANG-2, a pharmaceutical composition containing it, as well as a method for its preparation. Also a nucleic acid encoding the above antibody and a vector or host cell containing the aforementioned nucleic acid are disclosed.EFFECT: invention allows effective treatment of cancer and/or vascular diseases.12 cl, 19 dwg, 18 tbl, 20 ex

Antibodies against nerve growth factor and methods for their production and application // 2640252
FIELD: biotechnology.SUBSTANCE: invention relates to a method for production of antibodies suitable for use in horses that are specifically associated with the horse nerve growth factor (NGF) and neutralise the ability of the horse NGF to contact the horse NGF p75 or TrkA receptor and the corresponding antibodies. To implement this method, a donor antibody is obtained from a species other than a horse, the donor antibody having a binding specificity for the target antigen present in horses. Then, each amino acid residue in the sequence of the framework regions of the donor antibody is compared to each amino acid residue present at the corresponding position in the sequence of the framework regions of horse antibodies pool. Then, the identified amino acid residues in the donor antibody are replaced with the amino acid residues present at the corresponding position in the pool of horse antibodies. The resulting antibody does not contain any amino acid foreign at the corresponding position in horses, at any position within the framework regions. This invention also discloses a pharmaceutical composition and a kit containing the said antibodies for the treatment of pain or an NGF-induced tumour in horses.EFFECT: decrease or loss of antigen-binding activity is avoided.12 cl, 11 dwg, 8 tbl, 10 ex

ethod for introgression of pathogenic streptococcus genes in chromosomal dna of probiotic strain of enterococcus faecium l3 for expression in piles // 2640250
FIELD: biotechnology.SUBSTANCE: invention relates to a method of producing a live vaccine on the basis of biologically active strain Enterococcus faecium L3 due to the itrogression of the antigen of a clinically relevant pathogenic microorganism into the structure of the strain piles. This method involves producing a fusion gene of entF-bac, consisting of two separate gene fragments of probiotic E.faecium L3 and gene fragment bac and having a nucleotide sequence, shown in fig. 7a, its cloning and detection of bacterial clones expressing the desired protein in piles. The invention also relates to recombinant plasmid DNA pentF-bac. The real DNA pentF-bac is designed to create a live vaccine based on the biologically active strain of E. faecium L3. This pentF-bac DNA is a suicide plasmid pT7ERMB, at BamHI and KpnI sites of which the sequence of entF-bac fusion gene DNA is inserted. The present invention also relates to a vaccine preparation of E.faecium L3 Bac+. This vaccine preparation is prepared by electroporation of E. faecium L3 of plasmid pentF-bac DNA.EFFECT: invention allows for the production of a live vaccine based on the biologically active strain.3 cl, 9 dwg, 1 tbl, 5 ex

ethods, compositions and instruments for facilitation of regeneration // 2640249
FIELD: biotechnology.SUBSTANCE: methods for of promotion of tissue or organ regeneration in a patient by destroying partially functioning or not functioning cells or ageing cells containing glycation end-product, and for overcoming of effects of aging and a method for to selective destruction of ageing cells in a patient. The proposed methods involve administration of sn antibody that binds to the said final cell glycation product. The presented group of inventions is applicable in medicine.EFFECT: improved regeneration.20 cl, 1 dwg, 3 ex

Pharmaceutical composition for liver cancer treatment and/or prevention // 2640245
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for treatment and/or prevention of liver cancer with surface expression of a CAPRIN-1 protein, that contains an anti-CAPRIN-1 protein is provided. In addition, a pharmaceutical kit and a method for treatment and/or prevention of liver cancer expressing the CAPRIN-1 protein are observed.EFFECT: invention can find further application in liver cancer therapy.9 cl, 16 ex

Cd89 activation in therapy // 2640082
FIELD: pharmacology.SUBSTANCE: for CD89 activation neutrophil therapy, inflammations previously activated by a stimulus, are brought into contact with an effective dose of molecules that activate CD89 and contain Fc-alpha.EFFECT: CD89 activation increases apoptosis in neutrophils, which provides inhibition of inflammation in autoimmune and inflammatory diseases.18 cl, 13 dwg, 8 ex

ethods and compositions for asthma treatment using antibodies against il-13 // 2640025
FIELD: pharmacology.SUBSTANCE: method includes intravenous administration to an individual an antibody against IL-13 or its antigen-binding portion in a dose of about 0.3 mg/kg. Antibody against IL-13 or its antigen-binding portion contain a variable region of heavy chain SEQ ID NO:2 and variable region of light chain SEQ ID NO:3, where at least one pharmacokinetic characteristic, isolated from the group consisting of: (a) the maximum serum concentration (Smax), equal to about 55 to about 90 μg/ml, and (b) the area under the concentration-time curve for serum (AUC) which is equal to approximately 20000 up to approximately 34000 mcg/ml, is reached after administration of antibody or its antigen-binding part to a specified individual. The group of inventions also refers to variants of a method of treating bronchial asthma from mild to moderate form.EFFECT: optimum dosage and the schedule for administration of the above antibody to produce certain pharmacokinetic characteristics.9 cl, 4 ex, 7 tbl, 12 dwg

ethod for biological material obtaining for creation of autological antitumour vaccines // 2640017
FIELD: medicine.SUBSTANCE: invention can be used to isolate tumour antigens for tumour immunotherapy. For this, 1 gram of tumour is chopped on a cooled surface, 9 ml of buffer (pH 7.0) consisting of 10 mM of NaHCO3, 10 mM of EDTA, 2 mM of PMSF is added, and homogenized. Then it is centrifuged first at 20,000 g at 4°C for 30 minutes, and then at 100,000 g at 4°C for 90 minutes. The supernatant is subjected to ultra-/diafiltration using a membrane with a cut-off limit of 50 kDa, using a formulation buffer (pH 7.0) consisting of 10 mM of NaHCO3 and 150 mM of sodium chloride.EFFECT: obtaining of a fraction consisting of complexes represented by different classes of heat shock proteins, which determines a wide range of associated tumour peptides.1 ex, 2 tbl, 2 dwg

Computer-optimized antigens with wide reactivity spectrum for influenza viruses of h5n1 and h1n1 // 2639551
FIELD: biotechnology.SUBSTANCE: recombinant influenza hemagglutinin (HA) polypeptide to elicit an immune response to the H5N1 influenza virus containing the amino acid sequence from residues 2-568 of SEQ ID NO: 1 encoding its nucleic acid containing the proposed polypeptide fusion protein and virus-like particle (VLP) to elicit a response to the H5N1 influenza virus, an expression vector containing the nucleic acid, and an isolated cell containing it, a composition and method for eliciting an immune response to the H5N1 influenza virus, and a method for immunizing a subject are proposed. The proposed group of inventions can be used in medicine for immunization against the H5N1 influenza virus.EFFECT: proposed protein, VLP, and compositions are capable of eliciting an immune response with a wide range of reactivity to the H5N1 influenza virus.19 cl, 8 dwg, 5 ex

ethod for gm-csfrα inhibition in patient // 2639546
FIELD: medicine.SUBSTANCE: method for inhibition or neutralisation of the alpha chain activity of the colony-stimulating granulocyte/macrophage (GM-CSFRα) factor in a patient, comprising administration of a composition containing an effective amount of an antibody to human GM-CSFRα. In addition, methods for treatment of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease or myeloid leukaemia in a patient are contemplated. This invention may find use in the therapy of other diseases associated with GM-CSFRα.EFFECT: increased efficiency of treatment.12 cl, 9 dwg, 5 tbl

Antibodies and immunoconjugates and their applications // 2639543
FIELD: biotechnology.SUBSTANCE: humanized antibody specific for STEAP-1 and its antigen-binding fragment are proposed. A polynucleotide encoding an antibody or an antigen-binding fragment thereof, a vector, a host cell, a method for anti-STEAP-1 antibody production are described. A method for tumour visualization, a pharmaceutical composition, a medicament for cell proliferative disorder treatment, immunoconjugates and a cysteine-based antibody based on the said antibody are also disclosed.EFFECT: invention provides new antibodies to STEAP-1 and can be used in medicine.30 cl, 29 dwg, 2 tbl, 9 ex

ethods and compositions for autoimmune and inflammatory diseases treatment // 2639540
FIELD: biotechnology.SUBSTANCE: invention relates to an isolated antibody against RhoB, a fragment thereof, a composition containing it, as well as to a method for suppression of an inflammatory and/or autoimmune disease mediated by B cells and to a method of treatment of a condition or disorder associated with elevated levels of serum immunoglobulin for a subject in need, with its use. An isolated peptide for production of the above antibody is also disclosed, as well as a conjugate and a composition containing it.EFFECT: invention can effectively suppress an inflammatory or autoimmune disease mediated by B cells.19 cl, 10 dwg, 2 ex

Phospho-specific antibodies recognizing tau // 2639537
FIELD: medicine.SUBSTANCE: antibody and its fragment that bind to the phospho-epitope on the Tau protein, as well as the polynucleotides encoding them, are provided; cell lines that produce antibodies; a vector, its host cell and a method for production of the antibody and its functional fragment are proposed. In addition, a pharmaceutical composition, a method for treatment, alleviation or protection against taupathy; a method for induction of a passive immune response in an animal; a method for diagnosis of a protein tau-related disease, disorder or condition, or a predisposition to a protein tau-related disease; a method for monitoring of a minimal residual disease in a patient after treatment with an anti-tau antibody; a method for prediction of patient's response to treatment with an anti-tau antibody; methods for detection of phospho-Tau multimers (pTau) in a brain sample, including postmortem detection; a diagnostic set are proposed.EFFECT: invention can find further application in the diagnosis and therapy of diseases associated with Tau-protein.42 cl, 10 dwg, 15 tbl, 11 ex

Nucleic acid containing or coding histone "stem-loop" structure and sequence of poly (a) or polyadenylation signal, to increase expression of coded pathogenic antigen // 2639528
FIELD: biotechnology.SUBSTANCE: nucleic acid encoding a protein that is a pathogenic antigen, a histone stem-loop structure and a poly (A) or polyadenylation signal, a kit and a pharmaceutical composition containing one or more of said nucleic acid for treatment of an infectious disease, and a method for enhancement of expression of the encoded protein and the use of the said nucleic acid, kit or composition to enhance the encoded protein expression. The structure of the proposed nucleic acid, consisting of a combination of the poly (A) sequence or the polyadenylation signal elements in conjunction with the histone stem-loop structure, provides an increase in protein expression significantly above the level observed when using these elements separately.EFFECT: proposed group of inventions can be used in medicine for treatment of infectious diseases.26 cl, 24 dwg, 15 tbl, 11 ex

Fusion polypeptide containing wap domain and their application methods // 2639526
FIELD: biotechnology.SUBSTANCE: fusion proteins having at least one polypeptide of the human secretory inhibitor of leukocyte proteases (SLPI) operably linked to an immunoglobulin Fc fragment polypeptide having an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO:10 are obtained.EFFECT: invention allows to obtain a fusion polypeptide capable of effectively inhibiting the activity of neutrophilic serine proteases and thereby alleviating the symptoms of diseases or disorders associated with overexpression or serine protease activity in a subject in need thereof.15 cl, 4 dwg, 4 ex

Pharmaceutical composition for cancer treatment and/or prevention // 2639522
FIELD: pharmacology.SUBSTANCE: invention relates to an antibody that specifically binds to the CAPRIN-1 protein, as well as to a conjugate for treatment or prevention of CAPRIN-1 expressing cancer containing it. A pharmaceutical composition for CAPRIN-1 treatment or prevention, as well as a pharmaceutical combination for CAPRIN-1treatment or prevention containing the above antibody or conjugate is also described. The invention also relates to a method for treatment or prevention of a CAPRIN-1 expression cancer comprising administration of the above antibody, conjugate, composition or combination.EFFECT: invention allows effective treatment or prevention of CAPRIN-1 expressing cancer.12 cl, 8 ex

Immunity inducing agent // 2639518
FIELD: medicine.SUBSTANCE: invention refers to the immunity inducing agent containing the effective number of at least one polypeptide with inducing immune system activity, which induces cytotoxic t-cells capable to destroy tumour cells expressing polypeptide CAPRIN-1. Also, method is represented to obtain the selected antigen-presenting cell in vitro, which presents polypeptide fragment CAPRIN-1 for class I molecule RENAMO t-cells, as well as in vitro method for obtaining selected cytotoxic t-cells specific to protein CAPRIN-1. The invention also relates to a method of induction of immunity, including the introduction of individual effective amount of at least one polypeptide with inducing immune system activity, which induces cytotoxic t-cells capable to destroy tumour cells expressing polypeptide CAPRIN-1.EFFECT: effectively destroys tumour cells expressing the CAPRIN-1 polypeptide.13 cl, 5 dwg, 6 ex

Antibodies against vascular endothelial growth factor (vegf) // 2639506
FIELD: biotechnology.SUBSTANCE: method is described for blocking or reducing recurrent tumour growth or recurrent growth of cancer cells, comprising administering an effective amount of an anti-VEGF antibody to a subject in need of such treatment, wherein the anti-VEGF antibody comprises: HVR-H1 comprising the amino-acid sequence of SEQ ID NO: 1; HVR-H2 comprising the amino-acid sequence of SEQ ID NO: 2; HVR-H3 comprising the amino-acid sequence of SEQ ID NO: 3; HVR-L1 comprising the amino-acid sequence of SEQ ID NO: 4 or 5; HVR-L2 comprising the amino-acid sequence of SEQ ID NO: 6; and HVR-L3 comprising the amino-acid sequence of SEQ ID NO: 7, or wherein the anti-VEGF antibody comprises a heavy chain variable domain comprising the amino-acid sequence of SEQ ID NO: 43 and a light chain variable domain comprising an amino-acid sequence of SEQ ID NO: 44 or 45. A method of treating a non-neoplastic condition is also described is, comprising administering an effective amount of an anti-VEGF antibody to a subject in need of such treatment, wherein the anti-VEGF antibody is an antibody according to the above method.EFFECT: increased efficiency.19 cl, 16 dwg, 5 ex

Chemerical antigenes for vaccine against hepatitis c virus // 2639504
FIELD: pharmacology.SUBSTANCE: proposed inventions refer to chimerical antigens, vaccine composition, containing such a chimerical antigen, and use of chimerical antigen to obtain vaccines against hepatitis C virus (HCV). Described chimerical anetigen consists of a) the first segment, consisting of area E2 (amino acid 408-540) of HCV poliprotein, b) of the second segment, consisting of area E1 (amino acid 190-222) of HCV poliprotein, and c) of the third segment, consisting of Core area (amino acid 1-50) of this protein, in that order.EFFECT: strong immune response of a broad spectrum against various antigens of the virus.14 cl, 25 dwg, 7 ex

Liposomes containing oligopeptide fragments of myelin basic protein, pharmaceutical composition and method for multiple sclerosis treatment // 2639497
FIELD: biotechnology.SUBSTANCE: invention relates to the production of liposomes with a peptide of the myelin basic protein (MBP), and can be used in medicine for multiple sclerosis treatment. A composition is prepared containing the MBP peptide with SEQ ID NO: 11 or SEQ ID NO: 12 bound to the first vector, wherein the vector comprises a liposome having a surface exposed to the target portion that contains a mannose residue or a mannose derivative.EFFECT: invention provides greater therapeutic benefit than copaxone, therapeutically approved for the treatment of relapsing-remitting multiple sclerosis.18 cl, 14 dwg, 14 tbl, 14 ex

Virions and virus-like particles of alternanthera mosaic virus as amplifiers of immune response // 2639491
FIELD: medicine.SUBSTANCE: virus-like particles are produced in vitro from the protein of the alternanthera mosaic virus (AMV) coat in the absence of RNA. The virus-like particles are produced under physiological conditions by incubating the AMV coat protein in 0.15 M NaCl at pH 7.0-7.5. The group of inventions also relates to a method for enhancing an immune response to an antigen when immunizing animals or human with a mixture of an antigen and an adjuvant, wherein the virus-like AMV particles obtained by the above mentioned method are used as an adjuvant.EFFECT: use of this group of inventions allows to obtain stable and highly immunogenic virus-like particles which do not differ in size and morphology from full-fledged viral particles, while the AMV coat protein under in vitro physiological conditions can be repolymerised into long spiral structures in the absence of RNA.2 cl, 6 ex, 6 dwg

Quick-solving drug form of oral vaccine in which starch is used // 2639447
FIELD: pharmacology.SUBSTANCE: quick-solving drug form of solid oral vaccine contains an immunogenic quantity of antigenic preparation and an agent forming an immune response potentiating matrix consisting of 2.0% of modified starch (m/v), 2.4% of mannitol (m/v) and 1.2% of gelatine (m/v). An immune response is induced when the drug form is administered to a patient by placing in the oral cavity.EFFECT: effective stimulation of immunity against infection.11 cl, 12 dwg, 4 tbl

Composition for viral hepatitis c therapy // 2639388
FIELD: medicine.SUBSTANCE: invention can be used to treat an infection caused by the hepatitis C virus (HCV). A composition for HCV infection treatment of by the RNAi mechanism consists of complexes of lipopeptides of the OrnGlu (C16H33)2 composition, serving as a carrier, and siRNA molecules represented by 5'-AAAUCUCCAGGCAUUGAGCtt-3' (SEQ ID NO 1). Composition application on a transplantable cell culture of human hepatoma Huh-7, expressing the subgenomic replicon of HCV, causes a significant decrease in viral replicon expression by 20%.EFFECT: high bioavailability with subcutaneous administration of the composition.2 cl, 8 dwg, 4 tbl, 5 ex

Improved high-concentrated liquid preparations of antibodies against tnf-alpha // 2639386
FIELD: pharmacology.SUBSTANCE: group of inventions concerns a liquid aqueous pharmaceutical preparation containing a human anti-TNFα antibody, namely: adalimumab at a concentration of 100 mg/ml, 1 mg/ml of polysorbate-80, 42 mg/ml of mannitol and water. Also, methods for treatment of diseases associated with harmful TNFα activity, by drug administration to the patient are proposed.EFFECT: increased bioavailability with subcutaneous administration to the subject, reduction of pain associated with drug injection in the subject.21 cl, 26 tbl, 9 ex
ethod for anti-tick immunoglobulin production from donor immune plasma // 2639261
FIELD: medicine.SUBSTANCE: preliminary, according to the experimental data of plasma analyzes of a large group of donors, a prognostic calculation of the mean titer of antibodies to the tick-borne encephalitis virus (TBE) of the predicted boiler load (Tav.pred) by the following formula: where T1 is plasma titer of 1:10 IU or less; V1 is the volume of plasma with a titer of 1:10 IU or less; T2 is plasma titer of 1:20 IU; V2 is the volume of plasma titer of 1:20 IU; T3 is plasma titer of 1:40 IU; V3 is the volume of plasma titer of 1:40 IU; T4 is plasma titer of 1:80 IU; V4 is the volume of plasma titer of 1:80 IU; T5 is plasma titer of 1:160 IU; V5 is the volume of plasma titer of 1:160 IU; T6 is plasma titer of 1:320 IU; V6 is the volume of plasma titer of 1:320 IU.EFFECT: increased effectiveness of the use of donor immune plasma to obtain anti-tick immunoglobulin with a titer of antibodies to tick-borne encephalitis virus.2 ex

Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production // 2638457
FIELD: biotechnology.SUBSTANCE: antibodies of the invention specifically bind and block the type 1 receptor of fibroblast growth factor (FGFR1) and are characterized by amino acid sequences of H-CDR1, H-CDR2, H-CDR3, L-CDR1, L-CDR2 and L-CDR3. A pharmaceutical composition for oncological diseases treatment comprising the antibodies of the invention is provided, and a method for oncological diseases treatment, comprising administration of the antibodies of the invention to the patient. A method for antibodies production encoding their nucleic acids and cell lines for antibodies production is also provided.EFFECT: inventions allow to suppress tumour cells proliferation with high efficiency and specificity and inhibit tumour angiogenesis by blocking the pathological pathway, which in turn allows effective treatment of oncological diseases.22 cl, 5 tbl, 5 ex
ethod for directed destruction of cancer cells // 2638446
FIELD: medicine.SUBSTANCE: their preliminary visualization is performed by introduction of a complex consisting of combined photosensitizer molecules, fluorescent nanoparticles fluorescing in the infrared spectral region, and biological recognition molecules into the object under study. The complex further includes one or more plasmon nanoparticles. At that, semiconductor fluorescent nanocrystals that fluoresce in the infrared region of the spectrum are used as fluorescent nanoparticles. Irradiation of cancer cells localization is continued in the optical absorption range of fluorescent nanoparticles for detection of a fluorescent signal from fluorescent nanoparticles and subsequent induction cancer cells destruction process.EFFECT: method provides non-invasive detection and directed destruction of cancer cells localized at great depth, with increased efficiency of visualization and destruction of cancer cells.16 cl, 1 dwg, 1 ex

Lps vaccine // 2637448
FIELD: veterinary medicine.SUBSTANCE: vaccine composition includes a structure containing an O-antigen obtained from Salmonella as an active ingredient, provided that the said structure does not contain an entire cell, the said structure containing O-antigen is a lipopolysaccharide containing Lipid A. The method of the invention concerns obtaining of a vaccine composition, and comprises the steps of: gram-negative bacteria culturing, release of the above-mentioned structure from cells, collection and preparation of a solution of an O-antigen-containing structure.EFFECT: reduces inoculation reaction and reduces the amount of injection compared to the usual whole-cell vaccine.14 cl, 2 tbl, 6 dwg, 2 ex
ethod of obtaining live cultural attenuated vaccine for the prevention of varicella // 2637093
FIELD: medicine.SUBSTANCE: method of obtaining live cultural attenuated vaccine for the prevention of varicella includes infection with varicella-zoster virus strain of OKA diploid cells LEC-3 with the subsequent reproduction and the release of virus into cultural medium. Thereafter, at least one collection of the virus-containing liquid, the addition of a stabiliser and the preparation of the vaccine are carried out. The group of inventions also relates to the use of a strain of diploid LEC-3 cells for the production of a live cultural attenuated vaccine for the prevention of varicella. The use of diploid cells of strain LEC-3 with high adhesiveness to the surface of growth allows to obtain from 7 to 15 individual virus collections with a high content of extracellular vaccine Varicella zoster virus.EFFECT: obtaining extracellular virus Varicella zoster by individual collections from infected diploid cells LEC-3 using trisodium citrate provides increased harvest of Varicella zoster virus than in similar cultural models when used as a dispersant of trypsin.7 cl, 1 tbl, 3 dwg

yocardial infarction treatment using tgf-beta antagonists // 2637088
FIELD: medicine.SUBSTANCE: TGF-β antagonist is introduced, which is an antibody containing the VH-domain of PET1073G12 (SEQ ID NO: 2) and the VL-domain of PET1073G12 (SEQ ID NO: 7). Introduction is carried out within 72 hours from the onset of myocardial ischemia.EFFECT: reduced fibrosis, improved remodeling and myocardial function.20 cl, 2 tbl, 30 dwg, 6 ex

ethods and applications of inhibitors of proprotein convertase subtilisin/kexin, type 9 (pcsk9) // 2636820
FIELD: medicine.SUBSTANCE: proprotein convertase subtilisin/kexin 9 (PCSK9) is administered to a subject in need thereof, wherein the PCSK9 inhibitor is an antibody or an antigen-binding fragment thereof. Also, PCSK9 application is proposed for manufacture of a medicament for sepsis or septic shockr treatment. A pharmaceutical composition and a commercial package containing the PCSK9 inhibitor.EFFECT: possibility of treatment of a patient with sepsis or septic shock at doses suitable for intensive care.21 cl, 5 dwg, 7 tbl

Compositions and methods for treatment and prevention of infections caused by staphylococcus aureus // 2636780
FIELD: pharmacology.SUBSTANCE: composition is described comprising a pharmaceutically acceptable carrier and a purified monoclonal antibody comprising a heavy chain variable domain comprising CDR1, CDR2 and CDR3 and a light chain variable domain comprising CDR1, CDR2 and CDR3, wherein the monoclonal antibody specifically binds to protein A (SpA) Staphylococcus aureus with KD less than 1×10-10 M through its Fab site paratope. The monoclonal antibody is able to displace human IgG immunoglobulins associated with SpA on the surface of Staphylococcus aureus bacteria through their Fc regions.EFFECT: significant level of protection against lethal infection with Staphylococcus aureus strain.8 cl, 3 ex
 
2551087.
Up!